Adial Pharmaceuticals Notified by Nasdaq of Equity Deficiency

What Happened Adial Pharmaceuticals, Inc. announced on August 18, 2026 that Nasdaq notified the company it no longer meets the $2,500,000 stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1). The notice does not immediately affect the company’s listing or trading but starts a 45-calendar-day period for Adial to submit a plan to regain compliance.

Key Details

• Nasdaq notice date: August 18, 2026; compliance plan due within 45 days (deadline: October 2, 2026).
• Minimum equity required: $2,500,000 (Nasdaq Listing Rule 5550(b)(1)). Alternative standards noted but not met: $35 million market value of listed securities or $500,000 net income in specified years.
• If Nasdaq accepts a Compliance Plan, Adial may receive up to a 180-calendar-day extension from August 18, 2026 to regain compliance.
• Adial intends to seek stockholder approval at its 2026 Annual Meeting to convert outstanding Series A Non-Voting Convertible Preferred Stock and expects this action could help restore the required stockholders’ equity; no assurance it will obtain approvals or regain compliance. The company may request a Nasdaq hearing if needed, which would stay any delisting pending the hearing outcome.

Why It Matters This filing signals a Nasdaq listing compliance issue tied to Adial’s reported stockholders’ equity. For investors, the key risks are potential delisting proceedings if the company cannot regain compliance—although the notice itself does not suspend trading and several remedies (compliance plan, extensions, hearing) exist. The company’s planned conversion of preferred stock and submission of a compliance plan are its stated paths to return to compliance, but success is not guaranteed. The filing also includes standard forward-looking statement cautions about uncertainties.